Diadema Partners’s Roivant Sciences ROIV Stock Holding History

Diadema Partners’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-120,000	Closed	-$2.37M	–	188
2025 Q3	$1.82M	Buy	+120,000	New	+$1.49M	0.46%	63

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Diadema Partners's ROIV Position: Q4 2025 in Review

Diadema Partners sold out of Roivant Sciences (ROIV) in Q4 2025, closing a stake of 120,000 shares — an estimated $2.37M sold.

Diadema Partners first reported a position in ROIV in Q3 2025 and held it in 1 quarter. The position peaked at $1.82M in Q3 2025. 399 funds tracked by Wall St. Rank hold ROIV as of Q4 2025.

Diadema Partners reported no remaining Roivant Sciences position as of Q4 2025 after selling out during the quarter.
Diadema Partners sold 120,000 Roivant Sciences shares in Q4 2025, an estimated $2.37M.
Diadema Partners first reported a position in Roivant Sciences in Q3 2025 and held it in 1 quarter.
Diadema Partners's Roivant Sciences position peaked at $1.82M in Q3 2025.
399 funds tracked by Wall St. Rank held Roivant Sciences as of Q4 2025.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.